Myeloid Interferon Dendritic Cells for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies lack an effective cell type that can rapidly produce high levels of IFN-α in response to nucleic acids and simultaneously stimulate naive T cells, which is crucial for anti-viral responses and immune activation.
Innovation Solution
Identification and characterization of a novel dendritic cell type, myelos interferon DC (miDC), which produces IFN-α in response to nucleic acids and activates T cells, differing from conventional plasmacytoid DCs in survival rates and antigen presentation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If plasmacytoid DCs (pDCs) are used for IFN-α production, then high levels of IFN-α are produced in response to viral stimuli, but their ability to stimulate naive T cells is poor and their survival rate is low
Solution Approach 1:
The patent segments the immune response function into two distinct cell types: pDCs specialized for IFN-α production and miDCs specialized for T cell stimulation and survival. This segmentation allows each cell type to optimize its specific function without the compromises required by a single universal cell type, thereby resolving the contradiction between IFN-α production and T cell stimulation capability
Solution Approach 2:
The patent introduces miDCs as a universal cell type that can perform multiple functions: they produce IFN-α in response to nucleic acid stimuli, survive at high rates both before and after infection, and strongly stimulate naive T cells. This multi-functionality resolves the contradiction by providing a cell type that excels at all required functions simultaneously
2Reliability
If conventional DCs (cDCs) are used for T cell stimulation, then naive T cells are effectively stimulated, but their IFN-α production capability in response to viral stimuli is insufficient
Solution Approach 1:
The patent segments the immune response functions between cDCs and miDCs, with cDCs handling T cell stimulation and miDCs handling IFN-α production and survival. This functional segmentation allows each cell type to specialize and excel at its designated function, resolving the contradiction between T cell stimulation and IFN-α production
Solution Approach 2:
The patent introduces miDCs as an intermediary cell type that bridges the gap between innate immune detection (nucleic acid recognition) and adaptive immune activation (T cell stimulation). The miDCs receive nucleic acid stimuli, produce IFN-α, survive effectively, and simultaneously stimulate naive T cells, thereby mediating the connection between these immune functions and resolving the contradiction
3Device complexity
If a single DC type is used to perform both IFN-α production and T cell stimulation, then cell type complexity is reduced, but the effectiveness of both functions is compromised
Solution Approach 1:
The patent segments the dendritic cell population into distinct subsets (pDCs and miDCs) with specialized functions. This segmentation increases cellular diversity but improves overall system effectiveness by allowing each subset to optimize its specific function, thereby resolving the contradiction between simplicity and effectiveness
Solution Approach 2:
The patent identifies and utilizes specific phenotypic parameters (surface marker expression patterns) to distinguish and isolate different DC subsets with different functional capabilities. By changing and selecting for specific phenotypic parameters, the patent can enrich for miDCs that possess both high IFN-α production and high T cell stimulation capabilities, resolving the contradiction between functional effectiveness and cell type complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
miDCs effectively induce potent anti-viral responses and T cell stimulation, providing a novel approach for immunotherapy in treating infectious diseases and cancer by producing high levels of IFN-α and presenting viral antigens to naive T cells.
Implementation Method 1
They recognise pathogens and their products via the expression of numerous cell surface, endosomal and cytoplasmic pattern recognition receptors (PRR)
Implementation Method 2
the pDC continually present antigens on MHCII molecules once they are activated, and, as a result, can continue to present new viral antigens during the course of infection
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high T-cell stimulatory capacity.